TIDMAPH

RNS Number : 2184W

Alliance Pharma PLC

07 February 2017

 
 For immediate release   7 February 2017 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Changes to interests of a significant shareholder

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, has received a notification of a change in the interests of a significant shareholder. In accordance with AIM rule 17, the following details are now notified:

(a) Identity of the significant shareholder: River & Mercantile Asset Management LLP

(b) Date of disclosure: 6 February 2017

   (c)   Date of relevant change: 3 February 2017 

(d) Price, amount and class: 100,000 ordinary shares of 1p each; price not disclosed

(e) Nature of transaction: sale of shares

   (f)   Nature and extent of significant shareholder's interest: direct interest 

(g) Resultant shareholding: 4.98%

In compliance with DTR5, a copy of the notification received from this investor is appended.

For further information:

 
 Alliance Pharma plc                             + 44 (0) 1249 466966 
 John Dawson, Chief Executive 
  Andrew Franklin, Chief Financial 
  Officer 
 Rob Bellhouse, Company Secretary 
 www.alliancepharma.co.uk 
                                                     + 44 (0) 20 7466 
 Buchanan                                                        5000 
 Mark Court / Sophie Cowles 
  / Jane Glover 
 
                                                     + 44 (0) 20 7260 
 Numis Securities Limited                                        1000 
 Nominated Adviser: Michael 
  Meade / Freddie Barnfield 
 Corporate Broking: James 
  Black / Toby Adcock 
 

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 
 
 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 
--------------------------------------------------------------------------------------- 
 
 1. Identity of the issuer or                                   ALLIANCE PHARMA PLC 
  the underlying issuer 
  of existing shares to which 
  voting rights are 
  attached: 
---------------------------------------------------------  ---------------------------- 
 2 Reason for the notification (please tick the appropriate 
  box or boxes): 
--------------------------------------------------------------------------------------- 
 An acquisition or disposal of voting rights                            Yes 
----------------------------------------------------------  --------------------------- 
 An acquisition or disposal of qualifying financial                      No 
  instruments which may result in the acquisition 
  of shares already issued to which voting rights 
  are attached 
----------------------------------------------------------  --------------------------- 
 An acquisition or disposal of instruments with                          No 
  similar economic effect to qualifying financial 
  instruments 
----------------------------------------------------------  --------------------------- 
 An event changing the breakdown of voting rights                        No 
----------------------------------------------------------  --------------------------- 
 Other (please                                                          N/A 
  specify): 
--------------------------------------------------------    --------------------------- 
 3. Full name of person(s)                                  River and Mercantile Asset 
  subject to the                                                   Management LLP 
  notification obligation: 
---------------------------------------------------------  ---------------------------- 
 4. Full name of shareholder(s) 
  (if different from 3.): 
---------------------------------------------------------  ---------------------------- 
 5. Date of the transaction                                     3(rd) February 2017 
  and date on 
  which the threshold is 
  crossed or 
  reached: 
---------------------------------------------------------  ---------------------------- 
 6. Date on which issuer                                        6(th) February 2017 
  notified: 
---------------------------------------------------------  ---------------------------- 
 7. Threshold(s) that is/are 
  crossed or 
  reached:                                                              5% 
---------------------------------------------------------  ---------------------------- 
 
 
 
 8. Notified details: 
---------------------------------------------------------------------------------------------------------------------- 
 A: Voting rights attached to shares 
---------------------------------------------------------------------------------------------------------------------- 
 Class/type     Situation previous                Resulting situation after the 
  of             to the triggering                 triggering transaction 
  shares         transaction 
 
  if possible 
  using 
  the ISIN 
  CODE 
-------------  --------------------------------  --------------------------------------------------------------------- 
                Number           Number           Number         Number of                    % of voting 
                 of               of               of shares      voting                       rights 
                 Shares           Voting                          rights 
                                  Rights 
-------------  ---------------  ---------------  -------------  ---------------------------  ------------------------- 
                                                  Direct         Direct         Indirect      Direct        Indirect 
-------------      -----------    -----------    -------------  -------------  ------------  ------------  ----------- 
 GB0031030819   23,650,000       23,650,000       23,550,000     23,550,000                   4.9828% 
               ---------------  ---------------  -------------  -------------  ------------  ------------  ----------- 
 
 
 B: Qualifying Financial Instruments 
---------------------------------------------------------------------------------------------------------------------- 
 Resulting situation after the triggering transaction 
---------------------------------------------------------------------------------------------------------------------- 
 Type of            Expiration     Exercise/                       Number of voting               % of voting 
 financial           date           Conversion                      rights that                    rights 
 instrument                         Period                          may be 
                                                                    acquired if 
                                                                    the 
                                                                    instrument 
                                                                    is 
                                                                    exercised/ 
                                                                    converted. 
-----------------  -------------  ------------------------------  -----------------------------  --------------------- 
 
 
 C: Financial Instruments with similar economic effect 
  to Qualifying Financial Instruments 
---------------------------------------------------------------------------------------------------------------------- 
 Resulting situation after the triggering transaction 
---------------------------------------------------------------------------------------------------------------------- 
 Type of          Exercise       Expiration     Exercise/        Number of voting               % of voting 
 financial         price         date           Conversion        rights instrument              rights 
 instrument                                     period            refers to 
---------------  -------------  -------------  ---------------  -----------------------------  ----------------------- 
                                                                                                Nominal       Delta 
---------------  -------------  -------------  ---------------  -----------------------------  ------------  --------- 
 
 
 Total (A+B+C) 
---------------------------------------------------------------------------------------------------------------------- 
 Number of voting rights                            Percentage of voting rights 
-------------------------------------------------  ------------------------------------------------------------------- 
 23,550,000                                         4.9828% 
-------------------------------------------------  ------------------------------------------------------------------- 
 
 
 
 9. Chain of controlled undertakings through which the 
  voting rights and/or the 
  financial instruments are effectively held, if applicable 
--------------------------------------------------------------- 
 
 
 Proxy Voting: 
--------------------------------------------------------------- 
 10. Name of the proxy holder:            River and Mercantile 
                                          Asset Management LLP 
--------------------------------------  ----------------------- 
 11. Number of voting rights proxy                N/A 
  holder will cease to hold: 
--------------------------------------  ----------------------- 
 12. Date on which proxy holder will              N/A 
  cease to hold 
  voting rights: 
--------------------------------------  ----------------------- 
 
 
  13. Additional information: 
--------------------------------------  ----------------------- 
 14. Contact name:                         Charlotte Williams 
                                          Compliance Department 
--------------------------------------  ----------------------- 
 15. Contact telephone number:            +44 (0) 20 7601 6262 
--------------------------------------  ----------------------- 
 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUGUGUPUPMUBM

(END) Dow Jones Newswires

February 07, 2017 04:05 ET (09:05 GMT)

Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Alliance Pharma Charts.
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Alliance Pharma Charts.